Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cyclophosphamide
100%
Non-Hodgkin Lymphoma
100%
Etoposide
100%
Poor Prognosis
100%
Phase II Trial
100%
Idarubicin
100%
Confidence Interval
40%
First-line Therapy
40%
Continuous Intravenous Infusion
40%
Complete Response Rate
40%
Intermediate Grade
40%
Failure-free Survival
40%
Anemia
20%
Non-associated
20%
Response Rate
20%
Overall Survival
20%
In(III)
20%
Previously Untreated
20%
Life-threatening
20%
Doxorubicin
20%
Thrombocytopenia
20%
Granulocyte Colony-stimulating Factor (G-CSF)
20%
Age-adjusted
20%
Refractory Patients
20%
Treatment-related
20%
Infectious Complications
20%
Complete Response
20%
International Prognostic Index
20%
Low-risk Patients
20%
Overall Survival of Patients
20%
Leukopenia
20%
Relapsed Disease
20%
Poor Risk
20%
Second-line Therapy
20%
High-risk Factors
20%
Relapsed/refractory
20%
Medicine and Dentistry
Cyclophosphamide
100%
Etoposide
100%
Non-Hodgkin Lymphoma
100%
Phase II Trials
100%
Idarubicin
100%
Overall Survival
40%
Intravenous Drug Administration
40%
Failure Free Survival
40%
Anemia
20%
Infection
20%
Thrombocytopenia
20%
Infectious Complication
20%
Doxorubicin
20%
Granulocyte Colony Stimulating Factor
20%
Leukopenia
20%
International Prognostic Index
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Cyclophosphamide
100%
Etoposide
100%
Nonhodgkin Lymphoma
100%
Phase II Trials
100%
Idarubicin
100%
Overall Survival
40%
Failure Free Survival
40%
Infection
20%
Doxorubicin
20%
Anemia
20%
Thrombocytopenia
20%
Infectious Complication
20%
Granulocyte Colony Stimulating Factor
20%
Leukopenia
20%
Diseases
20%
Immunology and Microbiology
Cyclophosphamide
100%
Overall Survival
66%
Failure Free Survival
66%
Granulocyte Colony-Stimulating Factor
33%
Infectious Disease
33%
Infection
33%
Nursing and Health Professions
International Prognostic Index
20%